Abstracts Archive - Page 1772 of 2607 - ACR Meeting Abstracts

Abstract Number: 2598 • 2016 ACR/ARHP Annual Meeting
Conversion Rate of Tuberculosis Screening Tests in Patients with Rheumatic Diseases While Receiving Anti-Tumor Necrosis Factor Alpha (anti-TNFα) Agents
Syed Hasan Raza¹, Syed Islam², Amado Freire³, Debendra Pattanaik⁴ and John Stuart⁵, ¹Rheumatology, University of Tennessee Health Science Center, Memphis, TN, ²University of Tennessee Health Science Center, Memphis, TN, ³Pulmonology - Critical Care, University of Tennessee Health Science Center, Memphis, TN, ⁴Rheumatology, University of TN Health Science Center, Memphis, TN, ⁵Medicine, VA Medical Center, University of Tennessee Health Science Center, Memphis, TN
Background/Purpose: Risk of opportunistic infections, particularly mycobacterial infections, is increased among patients with rheumatic diseases treated with anti-TNF α agents. Therefore, screening of patients for…
Abstract Number: 2599 • 2016 ACR/ARHP Annual Meeting
TCZ Improves the Pro-Atherothrombotic Profile of Rheumatoid Arthritis Patients Modulating Endothelial Dysfunction, Netosis and Inflammation
Patricia Ruiz-Limon¹, Rafaela Ortega-Castro², IVÁN ARIAS DE LA ROSA², Carlos Perez-Sanchez², Yolanda Jiménez-Gómez², Maria Carmen Abalos-Aguilera¹, Pilar Font-Ugalde², Eduardo Collantes-Estévez², Alejandro Escudero-Contreras², Chary Lopez-Pedrera² and Nuria Barbarroja², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain
Background/Purpose: Inhibition of the interleukin IL-6 receptor pathway by tocilizumab (TCZ) is an effective treatment for rheumatoid arthritis (RA). TCZ reduces atherosclerosis markers and improves endothelial function.…
Abstract Number: 2600 • 2016 ACR/ARHP Annual Meeting
Tofacitinib Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Gaetane Nocturne^1,2, Farhad Tahmasebi³, Saida Boudaoud⁴, Bineta Ly⁵ and Xavier Mariette^6,7, ¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ²INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, ³INSERM 1184, Paris Sud University, Le Kremlin Bicetre, France, ⁴INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, ⁵INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁶Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, ⁷INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France
Background/Purpose: Disease activity is the main risk factor for developing lymphoma in patients with rheumatoid arthritis (RA). However, the impact of immunosuppressive drugs remains an…
Abstract Number: 2601 • 2016 ACR/ARHP Annual Meeting
A Cytometric Assay for Monitoring Adalimumab Immunogenicity and Drug Concentrations Can Distinguish Anti-Adalimumab Antibodies from Interference
Morgan Casal¹, Manda Ramsey¹, Larry W. Moreland² and Christian Fernandez¹, ¹Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Tumor necrosis factor inhibitor (TNFi) biologics are a mainstay of therapy for rheumatoid arthritis (RA) patients with disease-modifying antirheumatic drug failure. However, RA patients…
Abstract Number: 2602 • 2016 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Gaetane Nocturne^1,2, Bineta Ly³, Saida Boudaoud⁴, raphaèle seror^5,6, Laurence Zitvogel⁷ and Xavier Mariette^8,9, ¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ²INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, ³INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁴INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, ⁵Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ⁶INSERM U1184, Paris Sud University, Le Kremlin Bicetre, France, ⁷IGR - INSERM U1015, Villejuif, France, ⁸Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, ⁹INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of lymphoma linked to activity of the disease. Immunosuppressive drugs have been suspected to induce…
Abstract Number: 2603 • 2016 ACR/ARHP Annual Meeting
Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone
Ara H. Dikranian¹, Rubaiya Mallay², Mike Marshall³, Megan Francis-Sedlak³ and Robert J. Holt^4,5, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Suncoast Internal Medicine Consultants and Largo Med Center, Largo, FL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Medical Affairs, Horizon Pharma, Inc, Lake Forest, IL, ⁵College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL
Background/Purpose: Patients with RA have previously demonstrated significant differences in morning stiffness (MS), a debilitating symptom of RA, and other disease measures with delayed release…
Abstract Number: 2604 • 2016 ACR/ARHP Annual Meeting
Ultrasound and Immunological Changes and Associations after One Year of IL-6/IL- 6R Blockade with Tocilizumab in Rheumatoid Arthritis Patients
Cesar Diaz-Torne¹, Juan Jose De Agustin², Patricia Moya¹, Maria A. Ortiz³, Delia Reina⁴, Carme Moragues⁵, Sergi Ros⁶, Emili Gomez⁷, Enrique Casado Burgos⁸, Eli Garcia⁹, Manel Pujol¹⁰, Maria Pilar Lisbona Perez¹¹, Andrés Ponce¹², V Torrente¹³, P. Estrada¹⁴, Silvia Vidal³ and ECOCAT group, ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, ³Institut de Recerca Sant Pau, Barcelona, Spain, ⁴Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁵Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶Rheumatology, Hospital de Viladecans, Viladecans, Spain, ⁷Rheumatology, Hospital Clínic, Barcelona, Spain, ⁸Hospital Universitari Parc Taulí, Sabadell, Spain, ⁹Rheumatology, Hospital de Mollet, Mollet, Spain, ¹⁰Hospital Mútua de Terrassa, Terrassa, Spain, ¹¹Rheumatology, Hospital de Sabadell, Sabadell, Spain, ¹²Rheumatology. Internal Medicine, Hospital General de Granollers, Granollers, Spain, ¹³Hospital de L'Hospitalet, L'Hospitalet de Llobregat, Spain, ¹⁴Rheumatology, Hospital Moises Broggi, Barcelona, Spain
Background/Purpose: Management of RA patients has improved in the last two decades in part with the use of ultrasound (US) in daily clinical practice. The…
Abstract Number: 2605 • 2016 ACR/ARHP Annual Meeting
Therapy with Biologic Agents after Diagnosis of Solid Malignancies; Results from the Corrona Registry
Dimitrios A. Pappas^1,2, Sabrina Rebello², Mei Liu², Jennifer Schenfeld³, YouFu Li⁴, David H. Collier³ and Neil Accortt³, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Recently issued guidelines suggest that rheumatoid arthritis (RA) patients with previously treated solid malignancy may be treated as patients without such history (1). The…
Abstract Number: 2606 • 2016 ACR/ARHP Annual Meeting
Effect of Glucocorticoids on Clinical and Radiographic Efficacy Outcomes in Methotrexate-Naive Patients with RA Receiving Tofacitinib or Methotrexate Monotherapy: Analysis of Data from a Phase 3 Trial
Christina Charles-Schoeman¹, Désirée van der Heijde², Gerd Burmester³, Peter Nash⁴, Cristiano A.F Zerbini⁵, Carol A Connell⁶, Haiyun Fan⁷, Kenneth Kwok⁸, Eustratios Bananis⁷ and Roy Fleischmann⁹, ¹University of California, Los Angeles, Los Angeles, CA, ²Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁵Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, New York, NY, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often receive concomitant treatment with glucocorticoids (GCs) to…
Abstract Number: 2607 • 2016 ACR/ARHP Annual Meeting
Favorable Changes in Lipid Profile with Additive DMARD Therapy in Rheumatoid Arthritis Patients Failing Methotrexate Monotherapy
Tate Johnson¹, Ted R Mikuls², Harlan Sayles¹, Michael J. Duryee³, Geoffrey M. Thiele¹, Mary Brophy^4,5 and James R. O'Dell⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Heathcare System, Boston, MA, ⁵MAVERIC CSPCC (151MAV), VA Boston Healthcare System, Boston, MA, ⁶Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease is a significant comorbidity among RA patients. As such, dyslipidemia and the effect of DMARD therapy on lipid profiles is an important…
Abstract Number: 2608 • 2016 ACR/ARHP Annual Meeting
Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab
Atsushi Noguchi^1,2, Shinsuke Yasuda¹, Ryo Hisada¹, Kazumasa Ohmura¹, Sanae Shimamura¹, Yuka Shimizu¹, Masaru Kato¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, Miho Suzuki³, Yoshihiro Matsumoto⁴ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Product research department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ⁴Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Consecutive RA patients who initiated treatment with TCZ between December 2013 and September 2015 were enrolled in our prospective study. All patients met 2010…
Abstract Number: 2609 • 2016 ACR/ARHP Annual Meeting
The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated up to 19 Months with Tofacitinib
Kevin L Winthrop¹, Ann Wouters², Ernest H. Choy^3,4, Chudy Nduaka², Staci Abramsky², Pinaki Biswas², Lisy Wang⁵, Jennifer Hodge², Irina Lazariciu⁶, Koshika Soma², Christopher F Mojcik² and William F.C Rigby⁷, ¹Oregon Health and Sciences University, Portland, OR, ²Pfizer Inc, New York, NY, ³CREATE Center, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Great Britain, ⁴CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, ⁵Pfizer Inc, Groton, CT, ⁶Quintiles, Saint-Laurent, QC, Canada, ⁷Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk for herpes zoster (HZ), and vaccination is recommended in patients over the age of 50 years,…
Abstract Number: 2610 • 2016 ACR/ARHP Annual Meeting
Immunogenicity Assessment of Biologics in Clinical Studies in Chronic Inflammatory Disease: A Systematic Review
Boris Gorovits¹, Daniel Baltrukonis², Indranil Bhattacharya³, Mary A Birchler⁴, Deborah Finco², Daniel Sikema⁴, Michael S Vincent⁵, Sadiq Lula⁶, Lisa Marshall⁷ and Timothy Hickling¹, ¹Pfizer, Andover, MA, ²Pfizer, Groton, CT, ³Clinical Pharmacology, Pfizer, Cambridge, MA, ⁴Clinical Immunology, Glaxo Smith Kline BioPharmaceuticals, Upper Merion, PA, ⁵Inflammation and Immunology Research Unit, Pfizer, Cambridge, MA, ⁶Envision Pharma Group, London, United Kingdom, ⁷Inflammation Global Medical Affairs, Pfizer, Collegeville, PA
Background/Purpose: A portion of patients without clinical response to anti-inflammatory biologics have been shown to develop anti-drug antibodies (ADA).1 ADA prevalence varies widely among biologics,…
Abstract Number: 2611 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Seoyoung C. Kim¹, Daniel H. Solomon¹, James R. Rogers¹, Sara Gale², Micki Klearman², Khaled Sarsour² and Sebastian Schneeweiss¹, ¹Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at elevated risk for cardiovascular (CV) disease. Patients using tocilizumab (TCZ) may experience increased serum lipid levels. It…
Abstract Number: 2612 • 2016 ACR/ARHP Annual Meeting
Sero-Positivity for Rheumatoid Factor Is an Independent Predictor for Achievement of Good EULAR Response at 24 Weeks in ACPA Positive Rheumatoid Arthritis Patients Treated with Abatacept: Results from Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Shuji Asai¹ and Naoki Ishiguro², ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University, Nagoya, Japan
Background/Purpose: Abatacept is a new class of biologic agent for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to CD80/86.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].